openPR Logo
Press release

Active principle for cancer medication MGN1703 proven

10-25-2010 08:22 AM CET | Health & Medicine

Press release from: MOLOGEN

/ PR Agency: MOLOGEN AG - Department for Corporate Communiations
specialists in the research and development of innovative medications on the basis of DNA structures.

specialists in the research and development of innovative medications on the basis of DNA structures.

MOLOGEN AG has taken a significant step forward in the development of its cancer medication. A further evaluation sequence of data from the company’s clinical study shows by means of biomarkers the potential of the active ingredient in the therapy of cancer.

MOLOGEN AG has evaluated a further sequence of clinical data from the completed phase Ib trial with the cancer medication MGN1703. The analysis of biomarkers of the patients’ immune system exemplarily shows the effect of MGN1703 on the immune system of cancer patients. It was shown that the immune system of the patients is broadly activated and in a manner that is necessary for a successful battle with tumor diseases.

The exemplary data achieved from the clinical trial confirms the results shown in preclinical trials and in vitro studies.

Prof. Dr. Burghardt Wittig, Chairman of the scientific advisory board of MOLOGEN AG, has commented: ”The evidence of activation markers for all cellular check points of the immune system can now be shown for the first time in patients with heavily damaged immune systems. The scientific concept of dSLIM®, the molecule which is behind MGN1703, has been confirmed by this once again.”

The data was seen as very positive, in light of the health condition of the patients who were being treated in the already completed clinical study of phase Ib. The immune system of the patients had been severely damaged from several month-long pretreatments with various types of chemotherapy, and as such, a successful evaluation of the biomarkers can not be assumed per se.

Dr. Matthias Schroff, CEO of MOLOGEN AG, has responded very optimistically to these interim results: "We have additional data on hand which proves the comprehensive effect of MGN1703 on the immune system. My confidence - especially as a scientist - is greater than ever that our current Phase II/III study will show the efficacy of the medication. We have been able to establish a link in the chain of evidence with this which should be meaningful not only for our entire product pipeline, but also for investors."

The cancer medication MGN1703 is currently being investigated in the course of a phase II/III clinical study that is relevant for the approval in the treatment of metastasized colorectal cancer. The goal of the study is to significantly prevent the progression of the cancer significantly longer than has been possible with the treatment methods up to now. The study is currently being conducted at various study centers in Germany and Austria. First results shall be available after an interim evaluation in the first half of 2011

More: www.mologen.com/data/News/EN_Mitteilungen/2010/100930.shtml

The MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.

The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange. (ISIN DE0006637200).

Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM ® and MOLOGEN ® are registered trademarks of MOLOGEN AG.

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

MOLOGEN AG
Department for Corporate Communiations
Fabeckstr. 30
D-14195 Berlin

Contact:
Prof. Peter W. Hübner
Head of Corporate Communications

T. +49 - 30 - 84 17 88 - 38
F. +49 - 30 - 84 17 88 - 50
www.mologen.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Active principle for cancer medication MGN1703 proven here

News-ID: 148975 • Views:

More Releases for DNA

AUTUMN DNA Reviews: Here are what TOP CONSUMERS say about the AUTUMN DNA
As a human, there are some specific vitamins and nutrients required by your body to run efficiently. Without those vitamins and nutrients, you may encounter issues such as body weakness, fatigue, headaches, and an imperiled immune system in general. This sets you at the risk of getting ill, and in some cases, leads to the development of chronic conditions. With that said, they are not the only reasons why you should
DNA Paternity Testing Market Trends 2020 | Growth by Top Companies: DNA Diagnost …
The report begins with the overview of the DNA Paternity Testing Market and offers throughout development. It presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and future market opportunities along with drivers, trending segments, consumer behaviour, pricing factors and market performance and estimation. The forecast market information, SWOT analysis, DNA Paternity Testing market scenario, and feasibility study are
DNA Paternity Testing Market Rapidly Growing in Healthcare, Competitor Analysis …
The exclusive research report on the Global DNA Paternity Testing Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global DNA Paternity Testing Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. Overview of Global DNA Paternity Testing Market: This report studies the Global DNA Paternity Testing
DNA Testing Kits Market Progresses for Huge Profits by 2025 | Top Players- Ances …
Orian Research recently published a latest research report titled “Global DNA Testing Kits Industry 2019” which highlights top companies, DNA Testing Kits market segmentation by Types, Application and market division based on Geographical Locations. The DNA Testing Kits research report primarily focuses on providing in-depth research analysis and forecast for DNA Testing Kits Market from 2019 to 2025. Get Sample Copy at https://www.orianresearch.com/request-sample/965177 Global DNA Test Kits Market: Key Drivers and
DNA Testing Services Market 2019-2025: Statistics Influencing the Industry- MyHe …
DNA Testing Services Market report is based on present industry situations, market demands, business strategies utilized by prominent players involved in this market along with their growth synopsis. This report has been segmented into types, applications and regions. The report also comprises major drivers boosting this market. DNA Testing Services market worth about XX million USD in 2018 and it is expected to reach YY million USD in 2025 with
DNA Sequencing Market: DNA Sequencing Industry is Expected to Penetrate the Clin …
The global DNA sequencing market is forecast to grow to $6.6 billion over the year 2016 at the compounded annual growth rate of 17.5% as a result of emerging technologies in this field and its use in a number of applications. DNA sequencing industry is segmented into instruments and consumables, services, and workflow products. Instruments and consumables segment are the rapidly emerging segments accounting for about $2.2 billion by the year